Thackray Helen M.
- SEC CIK
- 0001589725
No open-market purchases or sales filed in the past year.
Current role at each company
- BCRX Biocryst Pharmaceuticals IncChief R&D Officeras of Apr 2, 2025
- IMGN ImmunoGen, Inc.Directoras of Feb 12, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Thackray Helen M. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
BCRX Biocryst Pharmaceuticals Inc
Chief R&D Officer4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 15, 2024 (view filing) | May 14 | 1 day | Thackray Helen M.Chief R&D Officer | PPurchase | +30.0K | $5.86 | +$175.8K | +12.4%272.1K after | |
| Apr 5, 2023 (view filing) | Apr 3 | 2 days | Thackray Helen M.Chief R&D Officer | SSale | −7.00K | $8.29 | −$58.0K | −3.3%207.3K after | 10b5-1 |
| Dec 19, 2022 (view filing) | Dec 15 | 4 days | Thackray Helen M.Chief R&D Officer | SSale | −3.13K | $10.89 | −$34.0K | −2.3%133.3K after | |
| Apr 4, 2022 (view filing) | Apr 1 | 3 days | Thackray Helen M.Chief R&D Officer | SSale | −7.60K | $16.20 | −$123.1K | −5.3%136.4K after |